Some see inhibitors as a lifetime of tests, bleeds, and complications.
Novo Nordisk helps them see a lifetime of possibilities.

Click on image to view ad details and full-size version on AdPharm.

To see all of this brand’s ads on AdPharm, click here

Charlie Kimball is a successful race-car driver who was diagnosed with Type 1 diabetes in 2007. He was forced to stop racing mid-season following this. This elaborate social media marketing effort aims to show diabetes suffers that even with diabetes, they can accomplish great things. Charlie resumed racing in 2008 and continues to claim podiums. Novo Nordisk teamed-up with Charlie in this effort to promote Levemir and Novolog brands of insulin.

This effort includes a Facebook fan page, a YouTube Channel, a Twitter account, a blog and a specific page on Novo Nordisk Care’s Website.

Click here to view the campaign details, full-size versions and links on AdPharm

Now approved for acquired hemophilia
With a life-threatening acquired hemophilia bleed, every minute counts.
Stop it with NovoSeven

For options on how to access NovoSeven, go to accessnovoseven.com or call 1-877-NOVO-777

Brand name: NovoSeven
Generic name/category: Eptacog alfa (activated)
Company: Novo Nordisk
Country/Market: USA, North America
Indication(s)/use: uncontrollable hemorrhage, acquired haemophilia
Target: Healthcare Professionals (HCP)
Tagline: Let nothing inhibit their passion
Medium: Print ad
Size/duration single-page
Publication/Aired: American College Of Emergency Physicians – April 2007

To see all of this brand’s ads on AdPharm, click here

Effective therapy for acquired haemophilia

NovoSeven is a highly effective intervention which promotes haemostasis at the site of injury, bypassing the need for factors VIII and IX.

Rapid response. Excellent efficacy. Low incidence of adverse events.

Brand name: NovoSeven
Generic name/category: Eptacog alfa (activated)
Company: Novo Nordisk
Country/Market: UK, Europe
Indication(s)/use: uncontrollable hemorrhage, acquired haemophilia
Target: Healthcare Professionals (HCP)
Tagline: Targeted bleeding control.
Medium: Print ad
Size/duration single-page
Publication/Aired: 2006

To see all of this brand’s ads on AdPharm, click here

Open up new horizons

Room temperature stable.

NovoSeven room temperature stable. Always at hand.

Targeted bleeding control.

Recombinant human factor VIIa (NovoSeven, eptacog alfa [activated], ATC code B02BD08) has been introduced for use in uncontrollable bleeding in hemophilia patients (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.

It is being increasingly used in uncontrollable hemorrhage. The first report of its use was in an Israeli soldier with uncontrollable bleeding in 1999. The rationale for its use in hemorrhage is, that it will only induce coagulation in those sites where tissue factor (TF) is also present. Still, O’Connell et al. report an increased risk of deep vein thrombosis, pulmonary embolism and myocardial infarction in association with the use of rhFVIIa.

According to a 2005 study, recombinant human factor VII improves outcomes in acute intracerebral hemorrhage.

More on Wikipedia

Agency: Life Healthcare

Brand name: NovoSeven
Generic name/category: Eptacog alfa (activated)
Company: Novo Nordisk
Country/Market: UK, Europe
Indication(s)/use: uncontrollable hemorrhage
Target: Healthcare Professionals (HCP)
Tagline: Targeted bleeding control.